Medical News

RSS

Washington, D.C, hosts 7th Annual World Health Care Congress

With the most sweeping changes to national health care policy now law, the 7th World Health Care Congress will feature the first post-reform gathering of the nation's top health care executives from all industry sectors.

5 Apr 2010

Today's Opinions and Editorials: Implementation of reform, questions of constitutionality and more on the individual mandate

The wisest course now is to replace the new health care law with immediate insurance reforms and step-by-step reductions in health care costs so that more Americans can afford to buy insurance (Sen. Lamar Alexander, 4/3).

5 Apr 2010

Autism individual to ring NASDAQ Opening Bell

In honor of National Autism Awareness Month this April, representatives from Autism Society will preside over the NASDAQ Opening Bell. Nicholas Medovitch, an individual with autism, will ring the bell.

5 Apr 2010

Aris Global introduces solution suite for integrating data from EDC and clinical safety

Aris Global, a leading provider of software solutions for the life sciences industry, today introduced Total Clinical 2.0, an integrated solution suite designed to help life science organizations enter clinical safety data once and share seamlessly across their enterprise. Total Clinical is available on a hosted, managed platform and includes a full range of delivery and support services.

5 Apr 2010

Peregrine's PS-targeting antibodies block HIV from entry into blood cells

Peregrine Pharmaceuticals, Inc. today announced the publication of data showing phosphatidylserine (PS)-targeting antibodies can block one of the key ways the AIDS virus gains entry into certain blood cells. The data were generated by scientists at Duke University as part of their ongoing AIDS vaccine research. The article titled "Anti-Phospholipid Human Monoclonal Antibodies Inhibit CCR5-Tropic HIV-1 and Induces β-Chemokines" is available online today and will be published in the April 12, 2010 edition of the Journal of Experimental Medicine.

5 Apr 2010

Canon receives FDA 510(k) clearance for CX-1 Hybrid Mydriatic/Non-Mydriatic Digital Retinal Camera

Canon U.S.A., Inc., a leader in medical imaging, today announced the Canon CX-1 Hybrid Mydriatic/Non-Mydriatic Digital Retinal Camera has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).

5 Apr 2010

Menstrual stem cells may help in treatment of stroke and central nervous system disorders

Cryo-Cell International, Inc. today announced results of a study published this month in the cover article of Stem Cells and Development showing that stem cells found in menstrual blood may one day be a potential source for stem cell therapies in stroke and other central nervous system disorders.

5 Apr 2010

Children's Hospitals and Clinics of Minnesota announces opening of new Cardiovascular Center

Children's Hospitals and Clinics of Minnesota is opening a new world-class Cardiovascular Center—the only one of its kind in the Upper Midwest—that integrates all pediatric cardiac services in one location. The new Cardiovascular Center reflects Children's dedication to family-centered care with all private patient rooms with the latest in technology for both the patient and care team, a state-of-the-art hybrid operating room, and 24/7 access to specially trained cardiac intensivists to ensure the best possible care for patients.

5 Apr 2010

Yongkangmen Health and Drug Chain Store to market and sell China Kangtai Cactus Biotech's products

China Kangtai Cactus Biotech Inc., a vertically integrated grower, developer, manufacturer and marketer of a variety of cactus-based products in China, announced today that it has signed a three-year marketing and sales agreement with Yongkangmen Health and Drug Chain Store Group Ltd. to sell its nutritious and patented cactus-based products, including nutraceuticals, health food, and health and energy drinks.

5 Apr 2010

Few veterans seek review of disability rating, panel finds

"Only a small fraction of wounded veterans who could get better benefits have applied in the two years since Congress, acting on concerns the military was cutting costs by downplaying injuries, ordered the Pentagon to review disputed claims," The Associated Press reports.

5 Apr 2010

Keryx Biopharmaceuticals' perifosine receives FDA Fast Track Designation

Keryx Biopharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for KRX-0401 (perifosine), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, for the treatment of refractory advanced colorectal cancer.

5 Apr 2010

AllCells expands office, laboratory production space and staff

AllCells LLC, a leading supplier of primary cell types, today announced it has completed its expansion into 10,000 additional square feet of office and laboratory production space located in Emeryville, California.

5 Apr 2010

Rexahn Pharmaceuticals submits Phase II protocol for study of Serdaxin in treatment of PD

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted a Phase II protocol to the U.S. Food and Drug Administration (FDA) for the clinical study of Serdaxin® for the treatment of Parkinson's disease (PD).

5 Apr 2010

Conference to combat health care fraud

With estimates of annual losses as much as $230 billion and legitimate costs also skyrocketing, the US health care industry is now looking to better control the impact of fraud. And with the ever-growing amount of data involving health care claims, new automated fraud-fighting capabilities are absolutely required.

5 Apr 2010

Methodist chooses Eclipsys HealthXchange solution for expanding care community access to clinical data

Eclipsys Corporation, The Outcomes Company®, today announced that The Methodist Hospital of Houston, TX, has selected Eclipsys HealthXchange™ to support it in connecting its local care community. The scalable and secure platform, powered by Medicity, will connect Methodist's acute care electronic health record (EHR) with a network of disparate EHRs in use at local affiliated physician offices throughout the region/local area.

5 Apr 2010

Ingen Technologies's SMART Nasal Cannula to be featured at upcoming Las Vegas MedTrade convention

Ingen Technologies, Inc., a leading manufacturer of respiratory medical devices, recently announced today that the SMART Nasal Cannula is a featured new product at the upcoming MedTrade convention in Las Vegas from May 10 through May 13, 2010. The Las Vegas MedTrade convention is the largest home health care expo in the world. Ingen is an exhibitor and will be part of the New Product showcase at MedTrade. The SMART Nasal Cannula is the Next-Generation of cannulas that improve oxygen therapy and reduce expenditures.

5 Apr 2010

Side effects may limit use of Prometheus's Lotronex for IBS

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that thought leaders believe Prometheus's Lotronex has efficacy advantages over current and emerging therapies for non-constipation predominant irritable bowel syndrome but side effects associated with the drug limit its use.

5 Apr 2010

Altheos to fund development of ATS907 Rho-kinase inhibitor with completed $20M Series A financing

Altheos, Inc., a privately held early-stage biopharmaceutical company, announced today that it has completed a $20 million Series A financing led by Bay City Capital. New investors Novo A/S, Canaan Partners, Life Science Angels and Atheneos Capital also joined the round. The financing will be used primarily for the development of ATS907, a selective Rho-kinase inhibitor Altheos licensed from Japanese pharmaceutical company Asahi Kasei Pharma. The license also includes a series of highly active compounds (AK138 series) specifically for topical treatment for glaucoma.

5 Apr 2010

Juventas Therapeutics commences enrollment in Phase I trial of JVS-100 for treatment of Class III heart failure

Juventas Therapeutics, a privately held, clinical-stage regenerative medicine company announced it has started enrolling patients in a Phase I clinical trial for JVS-100 to evaluate safety and efficacy in the treatment of patients with Class III heart failure. JVS-100 encodes Stromal Cell-derived Factor-1 (SDF-1) and has been shown in pre-clinical studies to significantly increase cardiac function by promoting cell survival and increasing new blood vessel formation in the damaged organ.

5 Apr 2010

FDA grants Keryx Biopharmaceuticals Fast Track designation for perifosine

Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that its partner, Keryx Biopharmaceuticals, was granted Fast Track designation by the U.S. Food and Drug Administration for perifosine (KRX-0401), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, for the treatment of refractory advanced colorectal cancer.

5 Apr 2010

Medical News

Washington, D.C, hosts 7th Annual World Health Care Congress

Today's Opinions and Editorials: Implementation of reform, questions of constitutionality and more on the individual mandate

Autism individual to ring NASDAQ Opening Bell

Aris Global introduces solution suite for integrating data from EDC and clinical safety

Peregrine's PS-targeting antibodies block HIV from entry into blood cells

Canon receives FDA 510(k) clearance for CX-1 Hybrid Mydriatic/Non-Mydriatic Digital Retinal Camera

Menstrual stem cells may help in treatment of stroke and central nervous system disorders

Children's Hospitals and Clinics of Minnesota announces opening of new Cardiovascular Center

Yongkangmen Health and Drug Chain Store to market and sell China Kangtai Cactus Biotech's products

Few veterans seek review of disability rating, panel finds

Keryx Biopharmaceuticals' perifosine receives FDA Fast Track Designation

AllCells expands office, laboratory production space and staff

Rexahn Pharmaceuticals submits Phase II protocol for study of Serdaxin in treatment of PD

Conference to combat health care fraud

Methodist chooses Eclipsys HealthXchange solution for expanding care community access to clinical data

Ingen Technologies's SMART Nasal Cannula to be featured at upcoming Las Vegas MedTrade convention

Side effects may limit use of Prometheus's Lotronex for IBS

Altheos to fund development of ATS907 Rho-kinase inhibitor with completed $20M Series A financing

Juventas Therapeutics commences enrollment in Phase I trial of JVS-100 for treatment of Class III heart failure

FDA grants Keryx Biopharmaceuticals Fast Track designation for perifosine

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Shaping the future of lab automation through AI and robotics

Latest News